Key facts
- It has raised $630K across 1 recorded rounds; the latest was Seed Round ($500K) in Jan 2026.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Embold Therapeutics
Funding rounds
1 roundsAbout Embold Therapeutics
Developer of a precision medicine platform designed to treat the root causes of neurodegenerative diseases such as Parkinson's disease. The company offers AI-optimized therapeutic enzymes, targeted discovery methods, and central nervous system delivery capabilities, enabling patients with genetically driven neurodegenerative disorders, to receive treatments that aim to slow disease progression and restore neuron function.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2023
- Website
- emboldtx.com/
- Ownership
- Privately Held (backing)
Embold Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Embold Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Embold Therapeutics in its N-PORT filings yet. We sweep new filings monthly.